Liver involvement in rheumatic diseases

Autor: Joanna Podgórska, Paulina Werel, Jakub Klapaczyński, Dorota Orzechowska, Mariusz Wudarski, Andrzej Gietka

Publikováno v: Rheumatology, Vol 58, Iss 5, Pp 289-296 (2020)

Liver involvement in rheumatic diseases may occur as a primary liver disease, primary rheumatic disease with hepatic manifestations or antirheumatic drug-induced liver disease. The aim of our article is to underline the importance of monitoring and c

Externí odkaz: https://doaj.org/article/dc4ab2bde7e0458f9767d4c35dcf6155

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

Autor: Paweł Rajewski, Dorota Zarębska-Michaluk, Ewa Janczewska, Andrzej Gietka, Włodzimierz Mazur, Magdalena Tudrujek-Zdunek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Dorota Dybowska, Waldemar Halota, Beata Lorenc, Marek Sitko, Aleksander Garlicki, Hanna Berak, Andrzej Horban, Iwona Orłowska, Krzysztof Simon, Łukasz Socha, Marta Wawrzynowicz-Syczewska, Jerzy Jaroszewicz, Zbigniew Deroń, Agnieszka Czauż-Andrzejuk, Jolanta Citko, Rafał Krygier, Anna Piekarska, Łukasz Laurans, Witold Dobracki, Jolanta Białkowska, Olga Tronina, Magdalena Wietlicka-Piszcz, Małgorzata Pawłowska, Robert Flisiak

Publikováno v: Journal of Clinical Medicine; Volume 11; Issue 17; Pages: 5193

Hepatitis C infection is one of the main reasons for liver cirrhosis and hepatocellular carcinoma. In recent years, more and more is being heard about extrahepatic manifestations of the hepatitis C infection including its possible influence on the de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d40a5750958c7bd8ac46659b155a3e8
https://pubmed.ncbi.nlm.nih.gov/36079122

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

Autor: Paweł Rajewski, Dorota Zarębska-Michaluk, Ewa Janczewska, Andrzej Gietka, Włodzimierz Mazur, Magdalena Tudrujek-Zdunek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Dorota Dybowska, Waldemar Halota, Beata Lorenc, Marek Sitko, Aleksander Garlicki, Hanna Berak, Andrzej Horban, Iwona Orłowska, Krzysztof Simon, Łukasz Socha, Marta Wawrzynowicz-Syczewska, Jerzy Jaroszewicz, Zbigniew Deroń, Agnieszka Czauż-Andrzejuk, Jolanta Citko, Rafał Krygier, Anna Piekarska, Łukasz Laurans, Witold Dobracki, Jolanta Białkowska, Olga Tronina, Magdalena Wietlicka-Piszcz, Małgorzata Pawłowska, Robert Flisiak

Publikováno v: Journal of Clinical Medicine, Vol 11, Iss 379, p 379 (2022)
Journal of Clinical Medicine
Journal of Clinical Medicine; Volume 11; Issue 2; Pages: 379

HCV infection is one of the main reasons for liver cirrhosis and hepatocellular carcinoma. In recent years, one finds more and more extrahepatic manifestations of HCV infection, including its possible influence on the development of diabetes. In the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da0916b9c8489adae174e8b8bde9a30
https://www.mdpi.com/2077-0383/11/2/379

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

Autor: Dorota Dybowska, Magdalena Tudrujek, A. Staniaszek, Zbigniew Deroń, Ewa Janczewska, Jerzy Jaroszewicz, Beata Dobracka, Iwona Orłowska, Marta Wawrzynowicz-Syczewska, Łukasz Laurans, Krzysztof Simon, Beata Lorenc, Robert Flisiak, Aleksander Garlicki, Olga Tronina, Teresa Belica-Wdowik, Andrzej Horban, Hanna Berak, Waldemar Halota, Dorota Zarębska-Michaluk, Marek Sitko, Małgorzata Pawłowska, Łukasz Socha, Barbara Baka-Ćwierz, Jolanta Białkowska, Anna Piekarska, Agnieszka Czauż-Andrzejuk, Włodzimierz Mazur, Krzysztof Tomasiewicz, Andrzej Gietka

Publikováno v: Journal of Interferon & Cytokine Research. 38:93-100

The aim of the study is to analyze treatments available for patients infected with genotype (G) 3 hepatitis C virus (HCV) in Poland at the beginning of the interferon (IFN)-free era and evaluate the efficacy and safety of different therapeutic option

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::401b928c5e554fb13dab3d3e04d35bc6
https://doi.org/10.1089/jir.2017.0113

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

Autor: Andrzej Horban, Agnieszka Czauż-Andrzejuk, Włodzimierz Mazur, Marek Sitko, Barbara Baka-Ćwierz, Robert Flisiak, Dorota Dybowska, Andrzej Gietka, Brygida Adamek, Teresa Belica-Wdowik, Waldemar Halota, Jolanta Citko, Aleksander Garlicki, Krzysztof Simon, Jerzy Jaroszewicz, Jolanta Białkowska-Warzecha, Anna Piekarska, Dorota Zarębska-Michaluk, Zbigniew Deroń, Marta Wawrzynowicz-Syczewska, Olga Tronina, Łukasz Laurans, Krzysztof Tomasiewicz, Ewa Janczewska, Iwona Buczyńska, Hanna Berak, Magdalena Tudrujek-Zdunek, Witold Dobracki, Łukasz Socha, Beata Lorenc

Publikováno v: BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Infectious Diseases

Background According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior interferon-based triple therapy with protease inhibitors (PI), is a combination of sofos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6414424d6382646d37dcfc81f09da6e
https://ruj.uj.edu.pl/xmlui/handle/item/144727